The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials

Overview of attention for article published in BMC Cancer, September 2014

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 10,382 followers.

"The efficacy & safety of crizotinib in ALK-positive non-small cell lung cancer: a meta-analysis of clinical trials." http://t.co/m21pgR6P5p

"The efficacy & safety of crizotinib in ALK-positive non-small cell lung cancer: a meta-analysis of clinical trials." http://t.co/m21pgR6P5p

"The efficacy & safety of crizotinib in ALK-positive non-small cell lung cancer: a meta-analysis of clinical trials." http://t.co/m21pgR6P5p

@gedefo_sefh: "The efficacy & safety of crizotinib in ALK-positive non-small cell lung cancer: a meta-analysis." http://t.co/voqlsRJ9AR

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.